Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC)

被引：25

作者：

Janne, Pasi A.

Ramalingam, Suresh S.

Yang, James Chih-Hsin

Ahn, Myung-Ju

Kim, Dong-Wan

Kim, Sang-We

Planchard, David

Ohe, Yuichiro

Felip, Enriqueta

Watkins, Claire

Cantarini, Mireiille

Ghiorghiu, Serban

Ranson, Malcolm

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[3] Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan

[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea

[5] Seoul Natl Univ Hosp, Seoul 110744, South Korea

[6] Asan Med Ctr, Seoul, South Korea

[7] Gustave Roussy, Villejuif, France

[8] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[9] Vall dHebron Univ Hosp, Barcelona, Spain

[10] AstraZeneca, Macclesfield, Cheshire, England

[11] Univ Manchester, Christie Hosp, Manchester, Lancs, England

来源：

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.8009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8009

引用

页数：1